Additionally, the pleiotropic actions of GLP-1 expand the therapeutic potential of GLP-1 agonists/analogues through combination with other drug classes, suggesting new scenarios in terms of enhancing cardio-renal protection and expanding clinical indications
In analysis of TTO based on parameter distributions and the valid cases, the median TTOs (Interquartile range) for SSIBs associated with semaglutide, liraglutide, dulaglutide, and exenatide were 15.5 (0.524.25, n = 18), 9.5 (0.561.5, n = 19), 35.5 (6.560.5, n = 11), and 2.5 (1.5169.5, n = 4) days, respectively (albiglutide was not included in the TTO analysis due to insufficient data)
doi:10.1001/jama.2024.2603 10 Lincoff AM et al.: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
coli, Enterococcus faecalis, Neisseria flava, and Vibrio cholera
The answer varies on several factors, including the specific peptides used, the individuals unique biochemistry, and the nature of the condition being treated
